Welcome to our dedicated page for Edap Tms news (Ticker: EDAP), a resource for investors and traders seeking the latest updates and insights on Edap Tms stock.
EDAP TMS SA (NASDAQ: EDAP) delivers innovative therapeutic ultrasound solutions for urological care through its HIFU and lithotripsy technologies. This news hub provides investors and medical professionals with essential updates on the company's advancements in robotic medical devices, regulatory milestones, and global market strategies.
Access real-time announcements including clinical trial results, product approvals, financial disclosures, and strategic partnerships. Our curated collection features press releases about EDAP's three operational divisions: HIFU tumor ablation systems, ESWL stone treatment devices, and distribution of complementary medical technologies.
Stay informed about developments in minimally-invasive treatment solutions that demonstrate EDAP's commitment to advancing urological care. The resource is regularly updated with material events affecting the company's position in the competitive medical devices sector.
Bookmark this page for streamlined access to verified information about EDAP's technological innovations, international expansion efforts, and research collaborations with leading medical institutions.
EDAP TMS (Nasdaq: EDAP), a global leader in robotic energy-based therapies, announced the appointment of Fran Schulz to its Board of Directors on July 8, 2024.
Schulz, an executive with over 35 years of experience in the healthcare industry, brings extensive expertise in strategic finance, accounting, and regulatory issues. She has been involved in over 100 equity and debt transactions, raising more than $15 billion.
Her appointment aims to strengthen EDAP's leadership as the company expands its Focal One platform globally. Schulz will advise on strategic growth initiatives, including expanding robotic HIFU technology to treat various diseases.
EDAP TMS SA, a leader in robotic energy-based therapies, announced new executive appointments to strengthen its European and Middle Eastern commercial operations. Damien Desmedt is appointed Vice President of Sales for EMEAI, bringing over 30 years of experience in healthcare innovations and robotic surgery. Alexander Fromm will serve as General Manager for Switzerland, overseeing strategic European territories with over 25 years in the medical device industry. The aim is to grow the Focal One technology platform and expand robotic HIFU applications in women’s health to meet unmet needs.
EDAP TMS SA, a leader in robotic energy-based therapies, announced that CEO Ryan Rhodes will present and host investor meetings at the Jefferies Global Healthcare Conference on June 5-6, 2024, in New York City. The presentation is scheduled for June 5th at 7:30 AM ET. A live and archived webcast will be accessible on the company's website.
EDAP reported robust growth in Q1 2024 with a significant 92% increase in U.S. Focal One® HIFU procedures year-over-year. HIFU revenue rose 10.2% to EUR 5.8 million ($6.3 million), contributing to a total revenue of EUR 14.9 million ($16.1 million), up 0.8% from Q1 2023. Gross profit increased to EUR 6.4 million ($6.9 million), driven by higher treatment revenues. Operating expenses dropped to EUR 11.2 million ($12.1 million) due to a non-recurring compensation expense in Q1 2023. Despite an operating loss of EUR 4.8 million ($5.2 million), net loss improved to EUR 4.5 million ($4.9 million) from EUR 7.5 million ($8.1 million) in Q1 2023. Additionally, EDAP's Phase 3 study on endometriosis is expected to yield results in the latter half of 2024.
EDAP TMS SA announced positive final results from the HIFI Study comparing Focal One® HIFU versus radical prostatectomy at the 119th AUA Annual Meeting. The study showed a higher salvage treatment free survival rate in the HIFU arm, better urinary continence and erectile function outcomes, and demonstrated the effectiveness and safety of robotic HIFU in managing localized prostate cancer. The study enrolled a total of 3,328 patients across 46 centers, highlighting the growing relevance of robotic HIFU in prostate cancer management.
EDAP TMS SA, a global leader in robotic energy-based therapies, will announce its first quarter 2024 financial results on May 16, 2024. The company will host a conference call and webcast with key executives to discuss the results. Investors can join the call to learn more about the financial performance and strategic direction of EDAP.
FAQ
What is the current stock price of Edap Tms (EDAP)?
What is the market cap of Edap Tms (EDAP)?
